NeuroPace Appoints Mark Saxton as Vice President of Sales

Industry veteran to drive business development, strategy and enhance customer experience

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the appointment of Mark Saxton as the company’s Vice President of Sales. Mr. Saxton is an accomplished medical device industry executive and drove the successful commercialization of multiple transformational technologies while holding a variety of sales and marketing roles over the last 25 years.

Prior to joining NeuroPace, Mark served as Vice President of Sales and Marketing for Ceterix Orthopaedics, the manufacturer of a novel meniscal repair system which was acquired by Smith & Nephew in 2018. Previously, Mr. Saxton served as Vice President of Product Solutions for Integer, a global healthcare leader dedicated to creating innovative medical technologies to enhance patients’ lives. His experience at Integer followed multiple positions of increasing responsibility, including his role as Vice President of Sales and Customer Service at VNUS Medical, which pioneered the minimally invasive treatment of venous reflux disease and was acquired by Medtronic.

Mark’s expertise in advancing medical technologies will be a tremendous asset to NeuroPace as the company prepares for the next phase of growth in the coming year,” said NeuroPace CEO Mike Favet. “We are thrilled to welcome Mark to the team at this exciting time for our company. His knowledge and impressive track record will help us achieve our mission to improve the lives of patients and families living with epilepsy.”

I am excited to join NeuroPace and further the company’s vision of leveraging groundbreaking technology to provide personalized treatment options to those living with refractory epilepsy,” said Mr. Saxton. “NeuroPace’s technology is a life-changing therapy for drug-resistant focal epilepsy, and I look forward to expanding patient and physician access to this important treatment option.”

The company’s RNS® System is the only device that monitors and responds to a patient’s unique brain patterns to deliver therapy that can stop seizures within milliseconds of detecting abnormal brain activity – even before symptoms occur.

About Epilepsy

One in 26 Americans will develop epilepsy in their lifetime, with approximately 150,000 new cases of epilepsy diagnosed annually. An estimated 3.4 million Americans currently live with epilepsy. Epilepsy is a chronic disorder, the hallmark of which is recurrent, unprovoked seizures. More people live with epilepsy than autism spectrum disorders, Parkinson’s disease, multiple sclerosis and cerebral palsy – combined.1

About the NeuroPace RNS System

The RNS System is the world’s first and only closed-loop brain-responsive neuromodulation system, designed to prevent seizures at their source. The RNS System is composed of a neurostimulator, leads that are placed at the seizure foci, a remote monitor used by patients to upload their data, and a RNS Tablet and Patient Data Management System (PDMS) used by physicians. Physicians can view their patient’s electrographic data on a secure website and program the device to personalize therapy for each individual. Unlike anti-epileptic drugs or resective surgery, brain-responsive neuromodulation outcomes typically improve with time and do not cause the cognitive side effects that can be associated with those alternatives. The RNS System is now available at nearly all comprehensive epilepsy centers in the United States and is widely covered by private and government insurance.

The RNS® System is an adjunctive therapy for adults with refractory, focal onset seizures with no more than 2 epileptogenic foci. See important safety information at https://www.neuropace.com/safety/

About NeuroPace

NeuroPace is the global leader in the emerging field of brain-computer interface technologies, which is projected to become a $1.2 billion market by 2024. We are dedicated to developing groundbreaking technology and advancing brain science to improve the quality of life for millions of individuals who suffer from neurological disorders. The company’s first product, the RNS System, is the only FDA-approved brain-responsive neurostimulator for the treatment of focal onset refractory epilepsy. In addition to treating epilepsy, brain-responsive neuromodulation holds the promise of treating other brain disorders that impact quality of life for millions of patients throughout the world.

1 Epilepsy Foundation. “Facts about Seizures and Epilepsy.”

http://www.epilepsy.com/learn/epilepsy-101/facts-about-seizures-and-epilepsy

Contacts

Media Contact

Lara Lingenbrink

[email protected]

(858)525-1414

error: Content is protected !!